Author

F. Gallais

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Assay:proteomics· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

L. Bellanger· 3 shared S. Debroas· 3 shared A. Velay· 2 shared D. Gouveia· 2 shared G. Miotello· 2 shared J. Armengaud· 2 shared J.-C. Gaillard· 2 shared L. Grenga· 2 shared

Activity by Year

2020-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

L. Bellanger

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Deep Mutational Engineering of broadly-neutralizing and picomolar affinity nanobodies to accommodate SARS-CoV-1 & 2 antigenic polymorphism

A. Laroche, M. L. Orsini Delgado, P. Cuniasse, S. Dubois, R. Sierocki, F. Gallais, S. Debroas, L. Bellanger, S. Simon, B. Maillere, H. Nozach

This study engineers nanobodies with picomolar affinity and broad neutralizing activity against SARS-CoV-1 and SARS-CoV-2 variants using Deep Mutational Engineering.

bioRxiv · Dec 7, 2021 · PreprintBiochemistry

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, , O. Schwartz

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

bioRxiv · May 26, 2021 · PreprintMicrobiology

Proteotyping SARS-CoV-2 virus from nasopharyngeal swabs: a proof-of-concept focused on a 3 min mass spectrometry window

D. Gouveia, G. Miotello, F. Gallais, J.-C. Gaillard, S. Debroas, L. Bellanger, J.-P. Lavigne, A. Sotto, L. Grenga, O. Pible, J. Armengaud

This paper demonstrates the use of mass spectrometry to detect SARS-CoV-2 peptides in nasopharyngeal swabs, showing potential for rapid and specific viral diagnosis.

bioRxiv · Jun 19, 2020Microbiology

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies.

A. Velay, F. Gallais, I. Benotmane, M.-J. Wendling, F. Danion, O. Collange, J. De Seze, C. Schmidt-Mutter, F. Schneider, P. Bilbault, F. Meziani, S. Fafi-Kremer

This study evaluates the performance of SARS-CoV-2 serological tools across different panels and timepoints, finding varying sensitivities and specificities with poor agreement between assays.

bioRxiv · Jun 16, 2020Microbiology

Shotgun proteomics of SARS-CoV-2 infected cells and its application to the optimisation of whole viral particle antigen production for vaccines

L. Grenga, F. Gallais, O. Pible, J.-C. Gaillard, D. Gouveia, H. Batina, N. Bazaline, S. Ruat, K. Culotta, G. Miotello, S. Debroas, M.-A. Roncato, G. Steinmetz, C. Foissard, A. Desplan, , J. Armengaud

This study uses shotgun proteomics to optimize viral particle antigen production for vaccines and analyze host cell proteome changes during SARS-CoV-2 infection.

bioRxiv · Apr 17, 2020Microbiology